Image of Immune checkpoint therapy for non-smallcell lung cancer: an update

LITERATURE

Immune checkpoint therapy for non-smallcell lung cancer: an update


The role of immunotherapy in treatment of non-small-cell lung cancer (NSCLC)
has been gaining interest over the past few years. This has been driven primarily
by promising results from trials evaluating antagonist antibodies that target coinhibitory
immune checkpoints expressed on tumor cells and immune cells within the
tumor microenvironment. Immune checkpoints exist to dampen or terminate immune
activity to guard against autoimmunity and allow for self-tolerance


Availability

REQJ621-04Titan CenterAvailable

Detail Information

Series Title
-
Call Number
-
Publisher : .,
Collation
-
Language
English
ISBN/ISSN
-
Classification
NONE
Content Type
-
Media Type
-
Carrier Type
-
Edition
-
Subject(s)
Specific Detail Info
-
Statement of Responsibility

Other version/related

No other version available


File Attachment



Information


RECORD DETAIL


Back To Previous